Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Sherr

Showing results (221-230 of 245) with videos related to

Pageof 25
Sort By:
Diabetes Care|February 2, 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention StudyDarrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, et al.
Diabetes Care|October 20, 2025
Erratum. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care 2025;48:1598-1606Lauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Diabetes Care|July 18, 2025
Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled TrialLauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Journal of Diabetes Science and Technology|May 2, 2022
Diabetes Technology Meeting 2021Nicole Y Xu, Kevin T Nguyen, Ashley Y DuBord, et al.
Journal of Diabetes Science and Technology|November 9, 2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery SystemViral N Shah, Anne L Peters, Guillermo E Umpierrez, et al.
Diabetes Research and Clinical Practice|July 19, 2022
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 SystemWilliam H Polonsky, Korey K Hood, Carol J Levy, et al.
Journal of Diabetes Science and Technology|January 27, 2023
Diabetes Technology Meeting 2022Jingtong Huang, Andrea M Yeung, Ashley Y DuBord, et al.
Diabetes Technology & Therapeutics|May 30, 2023
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 SensorToni L Cordero, Zheng Dai, Arcelia Arrieta, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
Diabetes Technology & Therapeutics|October 18, 2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 DiabetesAmy B Criego, Anders L Carlson, Sue A Brown, et al.
Pageof 25

Showing results (221-230 of 245) with videos related to

Sort By:
Pageof 25
Diabetes Care|February 2, 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention StudyDarrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, et al.
Diabetes Care|October 20, 2025
Erratum. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care 2025;48:1598-1606Lauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Diabetes Care|July 18, 2025
Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled TrialLauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Journal of Diabetes Science and Technology|May 2, 2022
Diabetes Technology Meeting 2021Nicole Y Xu, Kevin T Nguyen, Ashley Y DuBord, et al.
Journal of Diabetes Science and Technology|November 9, 2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery SystemViral N Shah, Anne L Peters, Guillermo E Umpierrez, et al.
Diabetes Research and Clinical Practice|July 19, 2022
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 SystemWilliam H Polonsky, Korey K Hood, Carol J Levy, et al.
Journal of Diabetes Science and Technology|January 27, 2023
Diabetes Technology Meeting 2022Jingtong Huang, Andrea M Yeung, Ashley Y DuBord, et al.
Diabetes Technology & Therapeutics|May 30, 2023
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 SensorToni L Cordero, Zheng Dai, Arcelia Arrieta, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
Diabetes Technology & Therapeutics|October 18, 2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 DiabetesAmy B Criego, Anders L Carlson, Sue A Brown, et al.
Pageof 25